AFP and hepatocellular carcinoma: The P4 panel had higher and more stable sensitivity than AFP + PIVKA-II in different clinical stages, especially in early HCC clinical stages like TNM I stage (0.875 vs 0.750), BCLC 0-A stage (0.902 vs 0.754), CNLC I stage (0.878 vs 0.683) (Fig. 6g, Supplementary Table 3).